Publication Date
| In 2025 | 0 |
| Since 2024 | 0 |
| Since 2021 (last 5 years) | 0 |
| Since 2016 (last 10 years) | 0 |
| Since 2006 (last 20 years) | 3 |
Descriptor
| Adolescents | 3 |
| Body Weight | 3 |
| Children | 3 |
| Drug Therapy | 3 |
| Mental Retardation | 3 |
| Pervasive Developmental… | 3 |
| Adults | 2 |
| Age Differences | 2 |
| Behavior Disorders | 2 |
| Symptoms (Individual… | 2 |
| Aggression | 1 |
| More ▼ | |
Author
Publication Type
| Journal Articles | 3 |
| Reports - Research | 2 |
| Reports - Evaluative | 1 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
| Aberrant Behavior Checklist | 1 |
What Works Clearinghouse Rating
Peer reviewed
Direct linkHellings, Jessica A.; Boehm, Danna; Yeh, Hung Wen; Butler, Merlin G.; Schroeder, Stephen R. – Journal of Mental Health Research in Intellectual Disabilities, 2011
We retrospectively reviewed clinic charts of 21 children and adolescents with developmental disabilities including autism spectrum disorders (ASD) treated consecutively with aripiprazole (ARI) for irritability and severe challenging behaviors. Data extracted include age, sex, and race; level of intellectual disability (ID); "Diagnostic and…
Descriptors: Symptoms (Individual Disorders), Body Composition, Mental Retardation, Autism
Hellings, Jessica A.; Cardona, Alicia M.; Schroeder, Stephen R. – Journal of Mental Health Research in Intellectual Disabilities, 2010
The objective of this study was to examine long-term adverse events of risperidone in 19 children, adolescents, and adults with Pervasive Developmental Disorders and intellectual disability, continuing risperidone for a mean of 186.5 weeks, following a 46-week risperidone study. Nineteen individuals continued long-term follow-up after our…
Descriptors: Mental Retardation, Pervasive Developmental Disorders, Drug Therapy, Safety
Hellings, Jessica A.; Zarcone, Jennifer R.; Reese, R. Matthew; Valdovinos, Maria G.; Marquis, Janet G.; Fleming, Kandace K.; Schroeder, Stephen R. – Journal of Autism and Developmental Disorders, 2006
Risperidone has shown safety and efficacy for aggressive and destructive behaviors in short-term studies. This longer-duration study includes a broad sample. Forty subjects, aged 8-56 years (mean=22), all with mental retardation and 36 with autism spectrum disorders participated in this 22-week crossover study, with 24 weeks of open maintenance…
Descriptors: Drug Therapy, Mental Retardation, Pervasive Developmental Disorders, Children
